Applied Clinical Trials Blog

Monthly Archives: August 2011

Azithromycin Reduces Exacerbations, At A Cost

By Kayda Norman | Published: August 29, 2011
Imagine that you lived in fear everyday that you would suddenly lose the ability to breathe. It could happen at any moment, and become so severe that you would need to be placed on ventilators. Oh, and your condition also happened to be the third leading cause of death in the United States. No big [...]
Posted in Uncategorized | Tagged , , , , | Leave a comment

Facebook: Should I Stay Or Should I Go?

By Pharmaceutical Executive | Published: August 26, 2011
We like to be heard if we’re willing to listen. And yet, until now, pharmaceutical companies with a presence on Facebook have understandably been reluctant to “listen” by allowing consumers to post comments on their Facebook pages. That changes on Monday, August 15, and the change leaves many pharma companies facing a dilemma. Most people agree [...]
Posted in CRO/Sponsor, Regulatory | Tagged , , , , , , , , | Leave a comment

Biosimilars Much to Learn and More to Come

By Lisa Henderson | Published: August 24, 2011
There’s been much talk about biosimilars this year, and forecasts pin the global biosimilars market at $19.4 billion by 2014, growing at an expected CAGR of 89.1% between 2009 and 2014. The development costs for a single biosimilar molecule hovers between a large span of $50 million and $200 million. So why all the attention? The [...]
Posted in CRO/Sponsor | Tagged , , , , , , , , , , , , , | Leave a comment

Remembering the Thalidomide Tragedy at ICPE 2011

By Wayne Kubick | Published: August 22, 2011
Things mostly had a familiar feel at this year’s International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in Chicago. The agenda was crammed with quick-paced research paper presentations, followed by cross-ex that seemed a bit gentler than usual, and the aisles were packed with posters frequently depicting the most esoteric and nuanced research topics, [...]
Posted in IT | Tagged , , , , , | 1 Comment

The Wait is Over

By Tim Denman | Published: August 19, 2011
The world is increasingly a now society. As members of the digital age we are accustomed to getting all the information we desire immediately. The appetite for the instant has taken control; why wait till tomorrow for information we can secure today. This tell-me-now attitude has effectively killed the suddenly old fashioned surprise. Nowhere is [...]
Posted in Uncategorized | Tagged , , , , , | Leave a comment

Have Your Say on Electronic Health Records!

By Peter ODonnell | Published: August 16, 2011
How much can the use of electronic health records (EHR) help in developing new medicines? How should their use be regulated? And will everyone be happy with this growing trend, anyway? If you have views on EHR (and if you haven’t, then you aren’t very close to the coalface of clinical trials!), then you also have [...]
Posted in IT | Tagged , , , , , , , | Leave a comment

HIV Treatment Highlights

By Kayda Norman | Published: August 15, 2011
Centers for Disease Control and Prevention estimates that more than one million people are HIV positive in the United Staes. Thankfully, there has recently been several advances in clinical trials and drugs for subjects with HIV.
Posted in Uncategorized | Tagged , , , , , , , | Leave a comment

Amid the Riots Comes Good News for London

By Philip Ward | Published: August 11, 2011
It’s been a dreadful few days for London and the UK as a whole. Scenes of rioting, looting, and indiscriminate violence have been shown across the world. The country’s not in turmoil and anarchy, as some sensationalist tabloid newspapers have suggested, but the troubles have come as a nasty shock to everybody. Amid all the negative [...]
Posted in Regulatory | Tagged , , , , , | Leave a comment

The Confusion Surrounding Comparative Effectiveness Research

By Richard Gliklich MD | Published: August 9, 2011
We all know, broadly speaking, the mission of comparative effectiveness research (CER), now sometimes called patient-centered outcomes research. Such studies should inform clinical and health policy decisions made by physicians, payers, and regulators to help determine treatment guidelines, coverage policies, and the therapeutic value of new therapies relative to standard-of-care in real-world settings.
Posted in IT | Tagged , , , , , , , | Leave a comment

Patient-Facing Trials

By Lisa Henderson | Published: August 5, 2011
I am writing a series of articles for the publication on the four major vendors in our space that are participating in Pfizer’s REMOTE trial–Mytrus, Exco InTouch, Greenphire, and Perceptive Informatics. Quest Diagnostics is part of this trial also, however, they are not specific to our industry.
Posted in Uncategorized | Tagged , , , , , , , , , | 1 Comment